2009 TOP 20 Biologics
- Category: FREE Reports
- Published on Tuesday, 09 March 2010 17:00
- Hits: 19920
The present FREE Download contains a compilation of the 2009 sales of recombinant biologic products including antibodies, proteins and peptides. The report provides an overview of the 20 best selling biologics (TOP 20 Biologics) and 2009 sales for each class of biologics as well as for selected antibodies, proteins and peptides.
TOP 20 Biologics Sales
The sales of the 20 best selling antibodies and proteins in 2009 are listed up, each of them posting more than US$ 1 bln sales in 2009.
Therapeutic Proteins Sales
The report compiles 2009 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH).
2009 sales of epoetin alfa and epoetin beta from Amgen, Johnson & Johnson (J&J), Roche, Chugai and Kirin are presented for their products Aranesp, Procrit, Eprex, Epogen, ESPO, Neorecormon and Epogin as well as for Dynepo and the biosimilar Binocrit.
Insulin & Insulin Analogs
2009 sales of insulin and insulin analog products from Novo Nordisk, Eli Lilly and Sanofi-Aventis are presented for their products Humalog (insulin lispro), Humulin, Lantus (insulin glargine), Levemir and Novolog (insulin analogue detemir and aspart) as well as for Actrapid, Novolin and others.
2009 sales of recombinant coagulation factor products factor VIIa, VIII and IX from Novo Nordisk, Bayer Schering Pharma, CSL, Baxter and Wyeth are presented for their products Novoseven (eptacog alfa), Kogenate FS (octocog), Helixate FS, Advate, Recombinate, Refacto, Benefix (nonacog).
Interferon alpha and beta
2009 sales of recombinant interferon beta and alfa products are presented for Avonex, Rebif, Betaferon / Betaseron from Biogen Idec, Merck Serono and Bayer Schering Pharma as well as for Pegasys, Peg-Intron and Intron A from Roche and Schering-Plough.
Granulocyte Colony-Stimulating Factor (G-CSF)
2009 sales of recombinant G-CSF products are presented for Neulasta (peg-filgrastim), Neupogen (filgrastim), GRAN (filgrastim) and Neutrogin (lenograstim) from Amgen, Kirin and Chugai.
Human Growth Hormone (hGH)
2009 sales of recombinant human growth hormone (somatostatin) products are presented for Genotropin, Norditropin, Humatrope, Nutropin / Protropin and Saizen / Serostim from Pfizer, Novo Nordisk, Eli Lilly, Genentech / Roche / Ipsen and Merck Serono as well as for the biosimilar Omnitrope.
Enzyme Replacement Therpay (ERT)
2009 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented for Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), Elaprase (idursulfase), Replagal (agalsidase alfa) and Naglazyme (galsulfase) from Genzyme, Biomarin, Shire and Dainippon Sumitomo.
Follicle Stimulating Hormone (FSH)
2009 sales of recombinant follicle stimulating hormone (FSH) products for treatment of infertility are presented for Gonal-f (follitropin alfa) and Puregon / Follistim (follitropin beta) from Merck Serono and Schering-Plough.
Therapeutic Antibodies Sales
The report compiles 2009 sales of the major therapeutic antibodies per class: cancer antibodies targeting CD20, Her2, VEGF and EGF-R, anti-TNF antibodies and ophthalmic and antiviral antibodies.
2009 sales of recombinant monoclonal antibody products are presented for Rituxan / MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab) and Vectibix (panitumumab) from Genentech / Roche, Bristol-Myers Squibb, Merch Serono, Imclone and Amgen.
2009 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab) and Cimzia (certolizumab pegol) from Amgen, Wyeth, Takeda Pharmaceuticals, Centocor (J&J), Schering-Plough, Tanabe Seiyaku, Abbott, Eisai and UCB.
Other Anti-Inflammatory Antibodies
2009 sales of recombinant monoclonal antibodies and fusion proteins such as Actemra/RoActemra or Orencia from Roche/Bristol-Myers Squibb.
2009 sales of the recombinant humanized antibody Synagis (palivizumab) targeting respiratory syncytial virus (RSV) for prevention of RSV infection in premature infants from MedImmune (AstraZeneca) are presented.
2009 sales of the recombinant humanized antibody fragment Lucentis targeting VEGF for treatment of age-related macular degeneration from Genentech (Roche) and Novartis are presented.
Selected Other Biologics
2009 sales of selected biologics (antibodies, proteins and peptides) are presented including the PTH products Forteo (teriparatide) from Eli Lilly, the GLP-1 analog Byetta (exenatide) from Eli Lilly and Amylin Pharmaceuticals, and the human growth factor rhBMP2 Inductos from Wyeth as well as botulinum toxin type A, glatiramer acetate (Copaxone), Xigris, Raptiva, Xolair, ReoPro, Integrilin, Tysabri, and others.
Table of Content
- Top Selling Classes of Biological Products
- Top 20 Blockbuster Biologics
- Anti-TNF Biologics
- Cancer Antibodies
- Insulin Products
- Interferon beta
- Rec. Coagulation FactorsEnzyme Replacement
- human Growth Hormone
- Interferon alfa
- Other Anti-Inflammatory Antibodies
- Ophthalmology Antibody
- Antiviral Antibody Follicle Stimulating Hormones
- Selected Other Antibodies
- Selected Other Proteins
- Selected Peptides